A Phase 1 Open-Label, Dose-Escalation Study to Evaluate Safety, Pharmacokinetic, and Biological Activity of INCB059872 in Subjects With Sickle Cell Disease
Phase of Trial: Phase I
Latest Information Update: 09 Jun 2017
At a glance
- Drugs INCB 59872 (Primary)
- Indications Sickle cell anaemia
- Focus Adverse reactions; Pharmacodynamics
- Sponsors Incyte Corporation
- 05 Jun 2017 Planned End Date changed from 1 Jun 2017 to 1 Jun 2018.
- 05 Jun 2017 Planned primary completion date changed from 1 Jun 2017 to 1 Jun 2018.
- 05 Jun 2017 Status changed from not yet recruiting to recruiting.